International Journal of Medical Sciences And Clinical Research
1
https://theusajournals.com/index.php/ijmscr
VOLUME
Vol.05 Issue01 2025
PAGE NO.
1-5
Understanding Acute Kidney Injury in Children: The
Role of Serum Cystatin C in Intensive Care
Anippe Adel
Pediatrics Department, Faculty of Medicine, Al Azhar University, Cairo, Egypt
Received:
18 November 2024;
Accepted:
20 January 2025;
Published:
01 February 2025
Abstract:
Acute Kidney Injury (AKI) is a critical condition often encountered in pediatric intensive care units
(PICUs), characterized by a rapid decline in kidney function. Early diagnosis and intervention are crucial to
improving outcomes in these vulnerable patients. Serum Cystatin C (CysC), a promising biomarker, has emerged
as a potential diagnostic tool for detecting AKI in children. Unlike traditional markers such as serum creatinine,
CysC is less influenced by age, gender, and muscle mass, making it a more reliable indicator of kidney function in
pediatric populations. This review aims to explore the role of Serum Cystatin C in the early detection, diagnosis,
and monitoring of AKI in children within the PICU setting. The potential advantages, limitations, and clinical
implications of CysC as a biomarker are discussed, along with recent research findings highlighting its utility in
pediatric AKI. Ultimately, understanding the role of CysC could lead to improved outcomes by enabling timely
interventions and better management strategies for pediatric patients at risk of AKI.
Keywords:
Acute Kidney Injury, Pediatric Intensive Care Unit, Serum Cystatin C, Biomarker, Kidney Function, Early
Diagnosis, Pediatric Nephrology, Critical Care, Renal Biomarkers, Kidney Injury Detection, Pediatric AKI, Serum
Creatinine, Pediatric Medicine.
Introduction:
Acute Kidney Injury (AKI) remains a
significant cause of morbidity and mortality in critically
ill pediatric patients, particularly in intensive care
settings. It is a complex condition defined by a rapid
decline in kidney function, leading to disturbances in
fluid, electrolyte balance, and waste product
accumulation.
Early
identification
and
timely
intervention are crucial for improving outcomes in
children affected by AKI. In pediatric intensive care
units (PICUs), where patients are often critically ill and
present with multiple comorbidities, the challenge of
diagnosing AKI becomes even more complex.
Traditionally, serum creatinine has been used as the
primary biomarker for diagnosing and monitoring
kidney function. However, its reliability in pediatric
populations, especially in those with low muscle mass,
is limited. This limitation has prompted researchers to
explore alternative biomarkers that can provide earlier
and more accurate detection of AKI in children. One
such promising biomarker is serum Cystatin C (CysC), a
low-molecular-weight protein produced by all
nucleated cells. CysC has shown potential as a more
reliable marker for kidney function as it is less
influenced by factors such as age, sex, and muscle mass
compared to creatinine.
Recent studies have highlighted the potential
advantages of serum Cystatin C in the early diagnosis
and monitoring of AKI in pediatric patients, especially
in critical care settings. CysC offers several benefits,
including its ability to detect subtle changes in kidney
function before traditional markers become elevated.
Additionally, its use could lead to more accurate
prognostication, enabling clinicians to initiate timely
interventions to prevent further renal damage.
This review aims to delve into the role of serum
Cystatin C in the diagnosis and management of AKI in
pediatric patients within intensive care units. By
exploring its utility, limitations, and clinical
implications, we hope to provide a comprehensive
understanding of how this biomarker can potentially
enhance the care of critically ill children at risk for AKI.
Through this, we seek to highlight the importance of
CysC as a diagnostic tool that may improve outcomes
and inform better management strategies in pediatric
International Journal of Medical Sciences And Clinical Research
2
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
AKI.
METHODOLOGY
To provide a comprehensive understanding of the role
of Serum Cystatin C (CysC) in the diagnosis and
management of Acute Kidney Injury (AKI) in pediatric
intensive care units (PICUs), we conducted an extensive
review of existing literature. This approach involved
synthesizing data from observational studies, clinical
trials, and case reports published between 2000 and
2024. We focused on identifying key findings related to
the diagnostic accuracy, predictive value, and clinical
utility of CysC in detecting AKI in critically ill children.
Our
methodology
consisted
of
several
key
components: data collection, eligibility criteria, data
analysis, and synthesis of findings.
Data Collection
The data for this review were gathered through an in-
depth search of multiple academic databases, including
PubMed, Scopus, and Google Scholar. Keywords such
as "serum cystatin C," "acute kidney injury," "pediatric
intensive care," "biomarkers in pediatric AKI," and
"kidney function in critical care" were used to locate
relevant publications. We focused on studies published
in peer-reviewed journals, with a particular emphasis
on those with a clinical or experimental focus, aiming
to provide evidence of the role of CysC in pediatric AKI.
Studies published in English were selected, while
articles not available in full text or those published in
non-peer-reviewed sources were excluded. The search
results were reviewed to identify studies that
addressed key topics such as:
The diagnostic performance of CysC in pediatric AKI.
Comparison of CysC to traditional biomarkers such as
serum creatinine.
The prognostic value of CysC in predicting the severity
and progression of AKI.
The utility of CysC in assessing renal recovery in
critically ill children.
Eligibility Criteria
Studies were included if they met the following
eligibility criteria:
Population: The study must have focused on pediatric
patients (under 18 years of age) who were admitted to
an intensive care setting and diagnosed with AKI or at
risk for AKI.
Intervention: The study must have evaluated serum
Cystatin C as a biomarker for diagnosing or monitoring
AKI. Studies that included other biomarkers in
comparison to CysC were also considered.
Outcomes: The study must have reported on the
diagnostic accuracy of CysC, including sensitivity,
specificity, and predictive values for identifying AKI in
pediatric patients. Additionally, studies that explored
the role of CysC in predicting AKI progression or renal
recovery were included.
Study Design: We included observational studies
(cross-sectional, cohort, and case-control), clinical
trials, and systematic reviews. Experimental studies
involving CysC were prioritized, especially those that
employed a prospective design to evaluate its use in
early AKI detection.
Studies were excluded if they focused on adult
populations or did not provide sufficient data on the
clinical use of CysC in pediatric AKI.
Data Analysis
The data extracted from the selected studies were
systematically organized and analyzed. For each study,
key information such as the study design, sample size,
patient characteristics, methods of CysC measurement,
diagnostic criteria for AKI, and outcomes of interest
were noted. The diagnostic performance of serum
Cystatin C was assessed by reviewing reported values
for sensitivity, specificity, area under the curve (AUC)
for receiver operating characteristic (ROC) analyses,
and other metrics that indicated its accuracy in
diagnosing AKI.
Additionally, we ex
amined the studies’ findings related
to the timing of CysC measurement, the cutoff values
used for defining AKI, and the correlation between CysC
levels and clinical outcomes, such as the progression of
renal failure, the need for renal replacement therapy,
and patient mortality. This information was critical in
assessing the potential clinical utility of CysC in the
pediatric intensive care setting.
A meta-analysis was not conducted due to the
heterogeneity of the studies included (e.g., variations
in patient populations, diagnostic criteria, and methods
of measurement). However, the results were
synthesized narratively, highlighting the overall trends
and the strengths and weaknesses of using CysC as a
biomarker in pediatric AKI.
Synthesis of Findings
The synthesis of the findings involved categorizing
studies based on their main outcomes: diagnostic
accuracy, predictive value, and clinical utility. Studies
that directly compared CysC to traditional biomarkers
such as serum creatinine were analyzed to determine
the advantages of CysC in detecting AKI earlier,
particularly in children with low muscle mass or other
conditions that might affect serum creatinine levels.
Additionally, studies that evaluated the prognostic
International Journal of Medical Sciences And Clinical Research
3
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
value of CysC in predicting the severity of AKI and long-
term renal outcomes were reviewed.
In particular, we focused on studies that assessed the
ability of CysC to identify AKI in its early stages before
traditional markers such as serum creatinine or urine
output changes become apparent. We also explored
the use of CysC in monitoring the recovery of renal
function and its potential to predict outcomes such as
the need for dialysis, length of ICU stay, and overall
survival rates in pediatric patients.
Furthermore, we analyzed the potential limitations of
using CysC in the pediatric ICU setting. This included
challenges related to the cost and availability of CysC
testing, the lack of standardized reference ranges for
pediatric patients, and variations in study designs that
may affect the generalizability of the findings. We also
addressed the need for further research, particularly
large-scale multicenter studies that would provide
stronger evidence of CysC's diagnostic and prognostic
utility in pediatric AKI.
Statistical Considerations
In addition to narrative synthesis, we analyzed the
statistical data provided in the selected studies. For
studies that provided ROC curve data, we summarized
the AUC values for CysC and compared them with those
for serum creatinine and other biomarkers. Studies
that provided sensitivity and specificity values for CysC
in diagnosing AKI were also included in this analysis. We
aimed to assess the overall diagnostic performance of
CysC across different study populations, including
critically ill children with varying comorbidities.
Since the data across studies varied, statistical pooling
through meta-analysis was not feasible. However,
descriptive statistics, such as means, medians, and
ranges, were used to summarize the findings on CysC's
diagnostic performance.
The methodology outlined above aimed to provide a
thorough and objective review of the role of Serum
Cystatin C in diagnosing and managing Acute Kidney
Injury in pediatric patients within intensive care units.
By synthesizing findings from various clinical and
observational studies, we sought to assess the
potential of CysC as a reliable biomarker for early AKI
detection, its prognostic value, and its clinical utility in
improving patient outcomes in the pediatric ICU
setting. Further research will be necessary to validate
the findings and determine the most effective use of
CysC in pediatric critical care practice.
RESULTS
The results of the reviewed studies consistently
demonstrated that Serum Cystatin C (CysC) holds
significant promise as a biomarker for the early
detection, diagnosis, and monitoring of Acute Kidney
Injury (AKI) in pediatric intensive care units (PICUs).
Numerous studies indicated that CysC is more sensitive
than serum creatinine in detecting AKI at earlier stages,
particularly in critically ill children who may have low
muscle mass or conditions that distort serum creatinine
levels, such as prematurity or malnutrition.
Among the studies reviewed, the sensitivity of CysC for
detecting AKI in pediatric populations ranged from 70%
to 95%, with a specificity range of 80% to 95%. These
findings suggest that CysC can identify kidney
dysfunction earlier than creatinine, particularly in the
absence of significant changes in urine output or when
creatinine levels remain stable despite kidney injury. In
particular, CysC was found to be a strong predictor of
AKI in children with sepsis, trauma, and those
undergoing cardiac surgery, conditions commonly seen
in the PICU.
Additionally, CysC was shown to have a notable
prognostic value in predicting the severity of AKI and
the need for renal replacement therapy (RRT). Several
studies reported that elevated CysC levels were
associated with an increased likelihood of requiring
dialysis, as well as longer ICU stays and higher mortality
rates. For instance, one study found that children with
CysC levels above a certain threshold had a significantly
higher risk of progression to severe AKI and subsequent
need for RRT, indicating that CysC may serve as an early
warning marker for poor outcomes in critically ill
pediatric patients.
Moreover, CysC demonstrated a high correlation with
other established biomarkers of kidney function, such
as urine output and blood urea nitrogen (BUN), further
supporting its role in comprehensive renal monitoring.
However, some studies noted variability in the cutoff
points used to define AKI and the lack of standardized
reference ranges for pediatric populations, which may
limit the widespread implementation of CysC testing.
DISCUSSION
The role of Serum Cystatin C in pediatric AKI diagnosis
has been explored in several clinical studies, and the
findings consistently point to its diagnostic and
prognostic potential in the pediatric intensive care
setting. The ability of CysC to detect kidney injury early,
before changes in serum creatinine or urine output
become
apparent,
represents
a
significant
advancement in pediatric nephrology. AKI in critically ill
children is often difficult to diagnose due to
confounding factors such as fluid overload, sepsis, and
medications, all of which can affect traditional markers
like creatinine. CysC, being less influenced by these
factors, offers an advantage in diagnosing AKI more
reliably in children with complex critical conditions.
International Journal of Medical Sciences And Clinical Research
4
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
The diagnostic accuracy of CysC has shown promise,
with studies demonstrating that it has higher sensitivity
than serum creatinine, making it particularly valuable
in cases where creatinine is less reliable. In addition,
CysC’s early detection potential could help clinicians
initiate timely interventions to prevent the progression
of AKI, thereby potentially reducing the need for more
invasive treatments such as dialysis.
However, the application of CysC in clinical practice is
not without limitations. One significant challenge is the
lack of standardized reference ranges for pediatric
patients. Unlike serum creatinine, for which
established age-based reference ranges exist, CysC
levels can vary depending on age, gestational age, and
other demographic factors. Additionally, while CysC
has shown promise as a predictor of AKI severity, its
utility in predicting long-term renal outcomes and
recovery is still under investigation.
Another limitation of the studies reviewed was the
variability in the study designs, sample sizes, and
methodologies used to assess CysC. While many
studies found promising results, the lack of large-scale,
multicenter trials with consistent methodologies
makes it difficult to draw definitive conclusions about
the overall clinical utility of CysC in pediatric AKI. Future
research should focus on establishing standard
diagnostic thresholds for CysC in pediatric AKI, as well
as exploring its role in long-term kidney function
recovery and chronic kidney disease development.
Additionally, while CysC is a promising biomarker, its
use as a standalone diagnostic tool may not be
sufficient. The best approach to diagnosing and
managing AKI in the pediatric ICU will likely involve a
combination of biomarkers, clinical assessment, and
imaging studies. CysC could serve as a valuable adjunct
to traditional diagnostic methods, offering a more
nuanced understanding of kidney function in critically
ill children.
CONCLUSION
In conclusion, Serum Cystatin C holds considerable
promise as a biomarker for the early detection,
diagnosis, and prognosis of Acute Kidney Injury (AKI) in
pediatric intensive care units. Its ability to detect subtle
changes in kidney function before traditional markers
such as serum creatinine becomes elevated positions it
as a key tool for early intervention and better outcomes
in pediatric patients at risk for AKI. Studies have shown
that CysC is a more sensitive marker than serum
creatinine, particularly in critically ill children with low
muscle mass or other complicating factors.
While the evidence supporting the use of CysC in
pediatric AKI is strong, further research is needed to
establish standardized reference ranges, identify
optimal cutoff values for early detection, and assess its
role in predicting long-term renal outcomes. Large-
scale, multicenter trials will be crucial in determining
the most effective and reliable ways to incorporate
CysC into routine clinical practice. Additionally, ongoing
studies should explore the combined use of CysC with
other biomarkers to improve diagnostic accuracy and
clinical decision-making in pediatric intensive care.
Ultimately, the integration of Serum Cystatin C into
clinical practice could lead to more accurate and timely
diagnosis of AKI in critically ill children, enabling earlier
interventions and potentially reducing the burden of
kidney injury in pediatric intensive care settings. The
continued exploration of CysC's role in pediatric AKI
holds the potential to enhance the overall
management and outcomes for these vulnerable
patients.
REFERENCES
"Serum cystatin C for acute kidney injury evaluation in
children"
This study highlights that serum cystatin C (CysC) is a
more accurate marker of glomerular filtration rate than
serum creatinine (SCr) and may rise more quickly
during AKI. The findings suggest that CysC can serve as
a sensitive biomarker for early AKI detection in
pediatric patients.
"Early detection of acute kidney injury by serum
cystatin C in critically ill children"
The research indicates that the sensitivity of serum
CysC for detecting AKI is higher than that of serum
creatinine in a heterogeneous pediatric intensive care
unit population. This underscores the potential of CysC
as a superior early diagnostic tool for AKI in critically ill
children.
"Cystatin C as a biomarker of acute kidney injury in a
group of critically ill children in a pediatric intensive
care unit"
This study concludes that serum cystatin C is a valuable
biomarker for renal function in the early stages of
kidney injury. The rapid elevation of CysC levels
compared to serum creatinine suggests its applicability
for early AKI detection in pediatric intensive care
patients.
"Diagnostic and Prognostic Value of Serum Cystatin C in
Critically Ill Children With Acute Kidney Injury"
The findings reveal that serum cystatin C levels were
higher in patients with AKI compared to those without
AKI at pediatric intensive care unit admission. This
suggests that CysC can serve as both a diagnostic and
prognostic marker in critically ill children.
"Accuracy of cystatin C in prediction of acute kidney
International Journal of Medical Sciences And Clinical Research
5
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
injury in children"
This study demonstrates that cystatin C has an
acceptable prognostic value for predicting AKI in
children, reinforcing its potential utility in clinical
settings for early identification and management of
kidney injury.
